EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
REGULATED INFORMATION
GHENT, Belgium, Jan. 18, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Perceptive Advisors LLC.
The above shareholders notified Ablynx that they have exceeded the 5% threshold on 12 January 2016 and now hold 2,773,439 Ablynx shares, representing 5.06% of the current 54,812,374 outstanding Ablynx shares.
Full versions of all transparency notifications are available on Ablynx website, under the section Investors.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has approximately 40 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: [email protected]
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: [email protected]
Follow us on Twitter @AblynxABLX
Ablynx media relations Instinctif Partners:
Sue Charles, Daniel Gooch
London office
t: +44 (0)20 7866 7905
e: [email protected]
Belgium/Dutch and French language
Jim Rusagara
Brussels office
t: +32 (0)2 626 9500
e: [email protected]
Pdf version of the press release http://hugin.info/137912/R/1979283/725054.pdf
HUG#1979283
